AbbVie Commits $100M to Morphic in Fibrosis Drug R&D Alliance

AbbVie is positioning itself to add fibrosis drugs to its pipeline through a new research and development partnership with startup Morphic Therapeutics.

Under the agreement, AbbVie (NYSE: ABBV) will pay Morphic $100 million up front for exclusive options to license the Waltham, MA, company’s fibrosis drugs. Morphic will be responsible for preclinical research and development.